EUVIMEDEUVIMED entdecken
Open Access

Hui‐Xiang Decoction Against Pancreatic Cancer by Regulating AKT and Activating the Hippo Signaling Pathway

Jian Zhang, Nannan Tang, Ao Gu, Jiatong Li, Meng-Yao Li iD

Chemistry & Biodiversity · 2026-05 · 23 (5)

DOI: 10.1002/cbdv.202502356 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Chemistry & Biodiversity, online erschienen am 14.05.2026. Verfasst von Jian Zhang und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Anesthesiology, Beijing Chao-Yang Hospital, Capital Medical University, Beijing, China. Hauptthemen laut MEDLINE: Hippo Signaling Pathway, Pancreatic Neoplasms, Drugs, Chinese Herbal, Adenocarcinoma. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 56 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Pancreatic cancer (PC) is a devastating disease with high mortality and a pressing need for safer, less toxic therapies. This study identifies Hui‐Xiang decoction (HXD), a formulation from food and medicine homology (FMH) herbs, as an effective and low‐toxicity treatment. We identified the presence of 122 active ingredients and 12 PC associated targets in HXD by network pharmacology. HXD and its active component, ammidin, effectively inhibited the proliferation and migration of PC cells. Furthermore, treatment with HXD in clinically relevant patient‐derived organoid (PDO) and xenograft (PDX) models significantly inhibited tumor growth, with minimal toxicity. Crucially, we found that HXD combats PC through a dual mechanism: simultaneously inhibiting the oncogenic EGFR/ErbB2/AKT1 pathway and activating the tumor‐suppressive Hippo signaling pathway. These results not only elucidate the molecular basis for HXD's efficacy but also provide a strong rationale for its potential application in the management of PC.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Hippo Signaling PathwayPancreatic NeoplasmsDrugs, Chinese HerbalAdenocarcinomaCell Line, TumorHumansAnimalsMiceMice, NudeOrganoidsXenograft Model Antitumor AssaysProto-Oncogene Proteins c-aktMolecular Docking SimulationNetwork PharmacologyErb-b2 Receptor Tyrosine KinasesErbB Receptors

Stichwörter der Autor:innen

EGFR/ErbB2/AKT1 axisHippo signaling pathwayHui‐Xiang decoctionfood and medicine homologypatient‐derived organoidspatient‐derived xenografts

Substanzen

Drugs, Chinese HerbalProto-Oncogene Proteins c-aktEGFR protein, humanERBB2 protein, humanErb-b2 Receptor Tyrosine KinasesErbB Receptors

Autor:innen und Institutionen

  • Department of Anesthesiology, Beijing Chao-Yang Hospital, Capital Medical University, Beijing, China.
  • State Key Laboratory of Systems Medicine for Cancer, Shanghai Cancer Institute, Renji Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China.
  • Department of Biliary-Pancreatic Surgery, Renji Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China.
  • Shanghai Key Laboratory of Cancer System Regulation and Clinical Translation, Jiading District Central Hospital, Renji Hospital Jiading Branch, Shanghai, China.

ORCID-Profile: Meng-Yao Li

Zitieren

APA

Zhang, J., Tang, N., Gu, A., Li, J., & Li, M. Y. (2026). Hui‐Xiang Decoction Against Pancreatic Cancer by Regulating AKT and Activating the Hippo Signaling Pathway. Chemistry & Biodiversity, 23(5). https://doi.org/10.1002/cbdv.202502356

Vancouver

Zhang J, Tang N, Gu A, Li J, Li MY. Hui‐Xiang Decoction Against Pancreatic Cancer by Regulating AKT and Activating the Hippo Signaling Pathway. Chemistry & Biodiversity. 2026;23(5). doi:10.1002/cbdv.202502356

BibTeX
@article{Zhang2026,
  author = {Zhang, Jian and Tang, Nannan and Gu, Ao and Li, Jiatong and Li, Meng-Yao},
  title = {Hui‐Xiang Decoction Against Pancreatic Cancer by Regulating AKT and Activating the Hippo Signaling Pathway},
  journal = {Chemistry & Biodiversity},
  year = {2026},
  volume = {23},
  number = {5},
  doi = {10.1002/cbdv.202502356}
}
Kostenlos starten →